Valneva has filed a patent for a method to produce lipidated proteins for vaccines against Lyme disease, Clostridium difficile, hMPV, and SARS-CoV-2. The method involves attaching fatty acids to glycerol and the N-terminal cysteine of specific proteins. GlobalData’s report on Valneva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Valneva, Anti-viral antigen-based compositions was a key innovation area identified from patents. Valneva's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Lipidated protein production method for vaccines against various diseases
See Also:
A patent application (Publication Number: US20240026412A1) discloses a method for producing a lipidated protein with one to three fatty acids attached to a glycerol and the N-terminal cysteine of the protein. The lipidated protein can have one fatty acid and a glycerol substituted with two fatty acids attached to the amino group of the N-terminal cysteine. The method involves specific conditions such as maintaining a pH of about 7, using a volume of at least 100 L, adding a trace element solution containing iron, cobalt, copper, zinc, and molybdenum during culturing, and incorporating an anti-foam agent like polypropylene glycol (PPG)-2000. The lipidated protein can be extracted from E. coli cell culture with a detergent and may include specific amino acid sequences or fusion proteins like Clostridium difficile toxins or SARS-CoV-2 Spike protein.
Furthermore, the method includes steps for controlling the additional headspace pressure, adding the trace element solution at specific dilutions during the culture phase, and incorporating the anti-foam agent during the exponential growth phase of E. coli. The lipidated protein produced according to the method can have specific composition ratios of peaks within the protein structure. Additionally, the patent application details the production of various lipidated proteins, including immunogenic variants with high sequence identity to specific proteins. The method also specifies the addition of the anti-foam agent in a controlled manner, either continuously or in boluses, during the feed phase of E. coli growth. Overall, the patent application outlines a comprehensive method for producing lipidated proteins with specific characteristics and compositions, highlighting the importance of precise conditions and additives in the production process.
To know more about GlobalData’s detailed insights on Valneva, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
